- Home
- MIST vs SPRO Comparison
MIST vs SPRO Comparison
Compare MIST & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | SPRO |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.9M | 71.0M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MIST | SPRO |
|---|---|---|
| Price | $0.92 | $1.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 355.5K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | $2,915.14 | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $0.98 | $1.08 |
| 52 Week High | $3.06 | $3.08 |
Technical Indicators
Market Signals| Indicator | MIST | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 31.92 | 33.05 |
| Support Level | N/A | $1.13 |
| Resistance Level | $1.42 | $1.29 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 3.49 | 14.29 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.